Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)

Eiger BioPharmaceuticals

Status and phase: Terminated; Phase 1

Conditions: Hepatitis D

Treatments: Drug: EBP921

Study type: Interventional

Funder types: Industry

Identifiers

NCT01316185

EBP-HDV 01-921-01

Details and patient eligibility

About

The purpose of this study is to assess the optimal dose of EBP921 by comparing the efficacy and safety of 2 dose regimens in patients with chronic HDV.

Full description

This is an open-label, phase 1b, proof-of-concept study to assess the safety and efficacy of EBP921, a prenylation inhibitor, in subjects chronically infected with delta hepatitis. Subjects will be randomized to receive one of two different doses of EBP921. Dosing will occur over 28-days and during that time, evidence of antiviral response will be assessed by frequent measurements of HDV-RNA via PCR assay. In addition, safety lab data will also be collected along with surveillance monitoring of HBV activity.

Enrollment: 3 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Men and women age 18 or older with the capacity to give written informed consent
2. Patients with compensated chronic HDV infection as indicated by presence of anti-HDV in serum.
3. Liver biopsy should be performed within one-year of study screening and graded using the Knodell scoring system.
4. Presence of HDV antigen in liver tissue or HDV-RNA in serum.
5. Active HBV replication will not exclude patients.
6. Previous therapy with standard alpha-interferon or peginterferon will not exclude patients.
7. Patients who are HBV therapy-naïve or who previously received HBV antiviral therapy will be eligible. Patients currently taking HBV antiviral therapy will e considered on a case basis.
8. Female subjects of reproductive potential and female partners of male subjects should be on two reliable forms of contraception from the start of the study until 60 days from the end of EBP921 dosing.

Exclusion criteria

1. Severe neuropsychiatric disorders

2. History or clinical manifestations of significant metabolic, hematological, pulmonary, ischemic heart disease, significant or unstable heart disease, gastrointestinal, neurological, renal, urological, endocrine, ophthalmologic disorders including severe retinopathy, or immune-mediated disease

3. Pregnant or breast-feeding patients or the inability to practice adequate contraception during the conduct of the study

4. Underlying autoimmune/immune-deficiency disease (e.g., lupus, sarcoidosis, celiac disease, HIV antibody positive, AIDS)

5. Chronic (> 4 weeks duration) diarrhea

6. Body weight > 128 kg and < 40 kg

7. Uncompensated cirrhosis

8. Absolute neutrophil count less than 1500 per cubic millimeter

9. Platelet count less than 90,000 per cubic millimeter

10. Evidence of concurrent HCV infection with positive serum HCVRNA

11. Evidence of hepatocellular carcinoma

12. Active substance abuse (alcohol, inhaled or injected drugs) within the past 12 months

13. Diagnosis of malignancy in the previous five years excluding superficial dermatologic malignancies

14. Any experimental therapy in the previous 6 months prior to enrollment.

15. Patients with a history of multiple drug resistant HBV 17. Patients receiving interferon therapy for any reason.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

3 participants in 2 patient groups

Group 1

Experimental group

Description:

Low Dose for 28 days: n=4

Treatment:

Drug: EBP921

Group 2

Experimental group

Description:

High Dose for 28 days; n=4

Treatment:

Drug: EBP921